Using the molecular classification of glioblastoma to inform personalized treatment.
Adriana Olar, Kenneth D Aldape
https://pubmed.ncbi.nlm.nih.gov/24114756/Actively Recruiting
Led by IRCCS San Raffaele · Updated on 2025-06-11
50
Participants Needed
1
Research Sites
47 weeks
Total Duration
Gliomas are the most common primary brain tumors in adults, with glioblastoma multiforme GBM being the most aggressive and associated with the poorest outcomes. Researchers are studying the role of glutamate, an amino acid important for brain function, in GBM growth and invasion. Alterations in glutamate synthesis and signaling may influence tumor aggressiveness, making it a focus for potential new treatments. The study involves measuring levels of glutamate and related proteins in blood, cerebrospinal fluid CSF, and tumor tissue from adult patients with brain lesions suspected to be GBM. These patients are candidates for complete tumor removal surgery followed by radiotherapy and chemotherapy. Samples will be collected at baseline before surgery and during follow-up visits at 3, 6, and 9 months. Molecular analyses and imaging, including MRI scans, will also be performed. Participants will undergo regular blood sampling and MRI scans at specified intervals to monitor glutamate levels and tumor progression. Researchers will assess changes in glutamate and its scavengers in serum and CSF over time to understand their relationship with disease activity. The study includes collection of clinical and imaging data throughout the follow-up period, with the total observation lasting at least 9 months after surgery.
CONDITIONS
Glutamate Excitotoxicity and Its Role in Glioblastoma Biology
S
Sincinelli Laura
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
IRCCS San Raffaele
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Baseline (before surgery)
Participants undergo blood, cerebrospinal fluid, and tumor sampling to measure glutamate and related proteins before surgery.
1 visit (in-person)
Duration - 9 months
Participants have MRI imaging and blood sampling at 3, 6, and 9 months after surgery to monitor glutamate levels and tumor progression.
Visits at 3, 6, and 9 months after surgery
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Adriana Olar, Kenneth D Aldape
https://pubmed.ncbi.nlm.nih.gov/24114756/Wook Joon Chung, Susan A Lyons, Gina M Nelson...
https://pubmed.ncbi.nlm.nih.gov/16079392/Roger Stupp, Warren P Mason, Martin J van den Bent...
https://pubmed.ncbi.nlm.nih.gov/15758009/Lorenzo Corsi, Andrea Mescola, Andrea Alessandrini
https://pubmed.ncbi.nlm.nih.gov/30978987/V I Teichberg, K Cohen-Kashi-Malina, I Cooper...
https://pubmed.ncbi.nlm.nih.gov/18423998/T Takano, J H Lin, G Arcuino...
https://pubmed.ncbi.nlm.nih.gov/11533703/Michael Roslin, Roger Henriksson, Per Bergström...
https://pubmed.ncbi.nlm.nih.gov/12622454/M Rijpkema, J Schuuring, Y van der Meulen...
https://pubmed.ncbi.nlm.nih.gov/12577293/Wen Wang, Guang Shi, Binbin Ma...
https://pubmed.ncbi.nlm.nih.gov/27337236/Stacey S Willard, Shahriar Koochekpour
https://pubmed.ncbi.nlm.nih.gov/23983606/IRCCS San Raffaele
Lead Sponsor